Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population (Q44126874)

30 November 2017

Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population (English)

1 reference

non-small-cell lung carcinoma

30 November 2017

1 reference

1 reference

Gu Ping

1

1 reference

30 November 2017

Wang Hui-Min

series ordinal

2

1 reference

30 November 2017

Wang Wei-Min

series ordinal

3

1 reference

30 November 2017

Han Bao-Hui

series ordinal

4

1 reference

30 November 2017

31 March 2010

1 reference

30 November 2017

1 reference

30 November 2017

28

1 reference

30 November 2017

2

1 reference

30 November 2017

578-583

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-010-9500-9

30 November 2017

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9500-9

21 January 2018

1 reference

12 December 2020

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials

1 reference

12 December 2020

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

10.1007/S12032-010-9500-9

Identifiers

DOI

1 reference

release_itfgz26jjzhxtotqtnpd7bmctu

30 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/itfgz26jjzhxtotqtnpd7bmctu

24 November 2022

mapped directly with Wikidata item

1 reference